Parkinson

Parkinson's Foundation Requesting Applications for 2024 Community Grants

Retrieved on: 
Thursday, November 9, 2023

NEW YORK and MIAMI, Nov. 9, 2023 /PRNewswire/ -- The Parkinson's Foundation has announced it is accepting applications for $1 million in community grant funding.

Key Points: 
  • NEW YORK and MIAMI, Nov. 9, 2023 /PRNewswire/ -- The Parkinson's Foundation has announced it is accepting applications for $1 million in community grant funding.
  • The 2024 community grants cycle will support health, wellness and educational programs that address unmet needs in local Parkinson's disease (PD) communities.
  • Community grants range from $10,000 to $25,000 per application, and the funding period will occur from July 1, 2024, to June 30, 2025.
  • Applications are due Jan. 31, 2024, and recipients will be announced in July 2024.

Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia's Digital Twins to be Presented at SfN 2023

Retrieved on: 
Wednesday, November 8, 2023

SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.

Key Points: 
  • SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.
  • The presentation will focus on results from two Digital Twins derived from The Alzheimer's Disease Neuroimaging Initiative (ADNI), The Parkinson's Progression Markers Initiative (PPMI) and Genetic cohort study.
  • Specifically, Aitia Gemini Digital Twins for AD and PD together identified 20 genes related to cytoskeleton disorganization demonstrating a potential mechanism for patient variability in disease progression.
  • Details of the abstract and poster presentation are as follow:

Follow Along With One Man’s Incredible Journey To Grab All Life Has To Offer After An Early-Onset Parkinson’s Diagnosis.

Retrieved on: 
Tuesday, October 31, 2023

For Mike Justak, it meant weathering the upcoming storm with boundless optimism and an unquenchable thirst for all that life has to offer.

Key Points: 
  • For Mike Justak, it meant weathering the upcoming storm with boundless optimism and an unquenchable thirst for all that life has to offer.
  • Discover his unique and motivating mindset in his new book, Puck Farkinsons: A Parkinson’s Memoir.
  • The memoir takes special care in showcasing Justak’s resilience in the face of the progressive and incurable disease.
  • For more information about the author, please visit any of his social media platforms:

Parkinson's Disease in 7 Major Markets Report 2023: Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

The "Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report encompasses the 7 Major Markets (US, France, Germany, Italy, Spain, UK, Japan) and includes an Excel-based forecast model for the Parkinson's Disease market, extending through the year 2029.
  • Anticipated growth in the PD market is driven by an increasingly aging population, complemented by the introduction of 14 pipeline products across the 7 Major Markets.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PD therapeutics market.

Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson’s Disease

Retrieved on: 
Tuesday, October 10, 2023

MADISON, Wis., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Stem Pharm, Inc., a drug discovery platform company leveraging 3D neuro-immune organoids and Verge Genomics, a biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, announced a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD).

Key Points: 
  • MADISON, Wis., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Stem Pharm, Inc., a drug discovery platform company leveraging 3D neuro-immune organoids and Verge Genomics, a biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, announced a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD).
  • The complexity and variability of the disease have posed significant challenges in the development of effective therapies.
  • Recognizing the urgent need for innovation, Verge and Stem Pharm have joined forces to leverage cutting-edge human-first technologies and expertise.
  • “We are incredibly excited to partner with Verge to apply our neuro-immune organoid platform to Parkinson’s disease,” said Steven Visuri, CEO of Stem Pharm.

Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023

Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J.

Key Points: 
  • Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J.
  • The Parkinson's Disease Therapeutics Conference is the Michael J.
  • Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development.
  • Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from academia and industry, showcasing the most exciting and innovative research from MJFF's research portfolio.

Mission Therapeutics to Present at Michael J. Fox Foundation's 15th Annual Parkinson's Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.

Key Points: 
  • Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
  • Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
  • A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
  • Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.

Mission Therapeutics to Present at Michael J. Fox Foundation's 15th Annual Parkinson's Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023

Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.

Key Points: 
  • Fox Foundation's Parkinson's Disease Therapeutics Conference on October 19, 2023, in New York.
  • Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's Disease and improved therapies for those living with the condition today.
  • A major unmet need for Parkinson's Disease patients is a treatment that slows or prevents the progression of disease.
  • Mission Therapeutics is currently developing two DUB inhibitors: MTX325 (targeting the CNS) and MTX652 (peripheral) which can potentially be used to treat any disease driven by mitochondrial dysfunction.

CurePSP Recognizes Three Prominent Medical Institutions for Their Care for PSP, CBD and MSA

Retrieved on: 
Thursday, October 5, 2023

PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.

Key Points: 
  • PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.
  • Additionally, autonomic dysfunction (e.g., blood pressure regulation, urinary control) is a hallmark feature of MSA, while PSP and CBD can present with cognitive impairment and difficulty expressing words.
  • "The continued growth of our care network is one impactful way we can work toward improving the standard of care for PSP, CBD and MSA."
  • "Through becoming a CurePSP Center of Care, our ability to care for our patients will only expand and strengthen," Dr. Brown said.

View from The Hill: 'Player' Mike Pezzullo undone by power play

Retrieved on: 
Monday, September 25, 2023

He dissed ministers in the way of these interests or those (and other people) he didn’t rate.

Key Points: 
  • He dissed ministers in the way of these interests or those (and other people) he didn’t rate.
  • He used Briggs to seek leverage with the then PMs, asking for his opinions to be passed on.
  • Nine says it learned of the messages “via a third party who obtained lawful access to them”.
  • He can perhaps be partly understood by referring back to the so-called bureaucratic “mandarins” of decades ago.
  • They ran their departments with iron grips, and in some cases were, or tried to be, as powerful as ministers, or more so.
  • (In a 2021 Anzac Day message to staff Pezzullo caused a public ruckus when he wrote of “the drums of war” beating.)
  • The player obsessed by security has been undone by some unidentified power play that has left him totally exposed.